Dr. Ludwig Kappos Awarded 2026 John Dystel Prize for Decades of Transformative Multiple Sclerosis Research

The 2026 John Dystel Prize is awarded to Dr. Ludwig Kappos for his transformative work in multiple sclerosis clinical trials, MRI monitoring, and disability scales.

By: AXL Media

Published: Mar 19, 2026, 5:57 AM EDT

Source: Information for this report was sourced from National Multiple Sclerosis Society

A Landmark Recognition in Clinical Neuroimmunology

The National Multiple Sclerosis Society and the American Academy of Neurology have jointly announced Dr. Ludwig Kappos as the winner of the 2026 John Dystel Prize, one of the most prestigious accolades in the field of neurology. Dr. Kappos, a leading figure at the University Hospital Basel in Switzerland, was selected for his comprehensive contributions to the science of clinical trials and the development of nearly all currently approved disease-modifying therapies. His career has been defined by a commitment to bridging the gap between high-level imaging science and practical clinical evaluations to improve the lives of those diagnosed with MS.

Standardizing Global Measures of Neurological Disability

One of the most enduring impacts of Dr. Kappos’ career is his work in refining the metrics used to evaluate patient health in a clinical setting. He was instrumental in establishing standardized versions of the Expanded Disability Status Scale, known as the Neurostatus-EDSS, which remains the primary tool for measuring neurological impairment in research trials worldwide. By creating a uniform language for disability, he enabled researchers across different continents to compare data accurately, accelerating the pace of pharmaceutical discovery and the validation of new medical interventions.

Pioneering Magnetic Resonance Imaging as a Diagnostic Pillar

Beyond disability scales, Dr. Kappos played a foundational role in integrating magnetic resonance imaging (MRI) into the standard of care for multiple sclerosis. Under his guidance, brain scans transitioned from experimental observations to essential tools for monitoring disease activity and evaluating the efficacy of new treatments. This shift allowed for a more objective understanding of how the disease progresses internally, often before physical symptoms manifest, and provided a reliable benchmark for determining whether a specific therapy was successfully suppressing inflammatory activity in the central nervous system.